This webinar is presented by Inari, now a part of Stryker

Disclaimer: These webinars are the sole content of the Industry Sponsors and do NOT constitute an endorsement by the SVS or the SVS Foundation for any products, therapies, or speaker remarks. The speakers are selected by the Industry Sponsors, and their remarks are their own.

Description
Up to 10% of patients with chronic limb-threatening ischemia (CLTI) have exhausted all conventional revascularization options and face a devastating risk of major amputation. Transcatheter arterialization of the deep veins (TADV) with the purpose-built LimFlow System is redefining what’s possible for these no-option patients by restoring blood flow to the foot through the venous system.

Following the encouraging limb-salvage and functional outcomes demonstrated in PROMISE I and the pivotal PROMISE II trial, the PROMISE III study takes the next step—prospectively examining both clinical outcomes and the physiologic maturation of the TADV circuit. In this exclusive webinar, investigators unveil the 6-month primary endpoint results from PROMISE III, showcasing real-world hemodynamic evolution, circuit maturation, and wound-healing patterns that deepen our understanding of how LimFlow works and who benefits most.

Join us for an in-depth discussion on how this innovative therapy is expanding treatment possibilities and reshaping the care paradigm for patients with no-option CLTI.

Speakers
Dr. Adam Gwozdz
Dr. Daniel Clair
Dr. Jocelyn Beach

Target Audience
Vascular Surgeon
Vascular Trainee
General Surgery Residents
Medical Students
Other types of Physicians
Vascular Nurses
Vascular Technologists
Physician Assistants
Nurse Practitioners
Hospital and Practice Administrators

This video is part of the Vascular Innovations Webinar Series